Labcorp Holdings Inc. (LH) Documents: SEC Filings, Investor Presentations & Press Releases

Labcorp Holdings Inc. (LH) documents, SEC filings and the IR site together: 159 documents, newest first; latest 2026-08-17. Read in-app with summaries. First-party data.

Documents — U.S. SEC EDGAR and the company's IR site
DateTypeDocument
2026-08-17Press releaseLabcorp to Host Investor Day on September 10, 2026
2026-08-178-KForm 8-K, Item 7.01
2026-08-148-KForm 8-K, Item 5.02
2026-08-10Press releaseLabcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma
2026-08-0510-QForm 10-Q for the quarter ended Jun 30
2026-08-04Press releaseLabcorp Launches FDA-Approved PTEN Companion Diagnostic for Prostate Cancer
2026-07-30Press releaseLabcorp Announces 2026 Second Quarter Results; Raises Full Year 2026 Guidance
2026-07-308-KForm 8-K, Item 2.02 results
2026-07-30TranscriptQ2 FY26 earnings call transcript
2026-07-27Press releaseLabcorp Launches Marker by Labcorp™ Genetic Health Panel, Expanding Consumer Access to Hereditary Genetic Risk Testing
2026-07-108-KForm 8-K, Item 7.01
2026-07-09Press releaseLabcorp Declares Quarterly Dividend
2026-06-30Press releaseLabcorp to Announce Second Quarter 2026 Financial Results on July 30, 2026
2026-06-308-KForm 8-K, Item 7.01
2026-06-22Press releaseLabcorp Announces Nationwide Availability of ColoSense®, the First FDA-Approved RNA-Based At-Home Colorectal Cancer Scre
2026-05-29Press releaseLabcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer
2026-05-28Press releaseLabcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side Effects
2026-05-278-KForm 8-K, Item 7.01
2026-05-268-KForm 8-K, Item 5.07
2026-05-0410-QForm 10-Q for the quarter ended Mar 31
2026-04-308-KForm 8-K, Item 2.02 results
2026-04-10ProxyDefinitive proxy statement
2026-04-098-KForm 8-K, Item 7.01
2026-03-318-KForm 8-K, Item 7.01
2026-03-208-KForm 8-K, Item 1.01
2026-02-2410-KAnnual report on Form 10-K, FY25
2026-02-18TranscriptQ4 FY25 earnings call transcript
2026-02-178-KForm 8-K, Item 2.02 results
2026-02-098-KForm 8-K, Item 5.02
2026-01-298-KForm 8-K, Item 1.01
2026-01-158-KForm 8-K, Item 7.01
2026-01-148-KForm 8-K, Item 7.01
2025-12-308-KForm 8-K, Item 7.01
2025-12-158-KForm 8-K, Item 5.02
2025-12-108-KForm 8-K, Item 5.02
2025-11-248-KForm 8-K, Item 5.02
2025-10-3110-QForm 10-Q for the quarter ended Sep 30
2025-10-288-KForm 8-K, Item 2.02 results
2025-10-088-KForm 8-K, Item 7.01
2025-09-258-KForm 8-K, Item 7.01

LH overview · LH earnings · LH financials · LH KPIs · LH ownership · LH peers

Data sourced from U.S. SEC EDGAR and the company's investor-relations site. Not personalized investment advice.